# Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

> **NCT01170052** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Charite University, Berlin, Germany** · enrollment: 20 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Temsirolimus
- **DRUG:** Bendamustine
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01170052
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-05
- **Primary completion:** 2012-04
- **Final completion:** 2014-04
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** insufficient enrollment
- **Last updated:** 2011-03-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01170052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01170052, "Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01170052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*